A Spectrum of Novel Mutations in the Protoporphyrinogen Oxidase Gene in 13 Families with Variegate Porphyria
To the Editor:
Variegate porphyria (VP) (OMIM 176000), one of the acute hepatic porphyrias, is caused by a partial de®ciency of protoporphyrinogen oxidase (PPO) (EC 1.3.3.4) , the penultimate enzyme in the porphyrin-heme biosynthetic pathway. Clinically, cutaneous and/or neuropsychiatric symptoms can occur in affected individuals (Bickers et al, 1993; . The cutaneous ®ndings include photosensitivity, increased cutaneous fragility, and blistering on the sun-exposed areas of the skin. Neurologic symptoms can present as acute porphyric attacks, including abdominal pain, muscle weakness, and respiratory paralysis that can lead to coma and death (Crimlisk, 1997; .
VP is usually inherited in an autosomal dominant fashion with incomplete penetrance. The human PPO cDNA and gene were recently cloned and mapped to chromosome 1q22±23 (Nishimura et al, 1995; Taketani et al, 1995) , and mutations were identi®ed in several families with VP (Deybach et al, 1996; Lam et al, 1996a, b; Meissner et al, 1996; Roberts et al, 1996 Roberts et al, , 1998 Warnich et al, 1996; Dailey and Dailey, 1997; deRooij et al, 1997; Kauppinen et al, 1997; Frank et al, , 1998a±e, 1999a Frank et al, , 2001 Corrigall et al, 1998; Whatley et al, 1999) .
Here, we studied VP patients of different ethnic origin, ages, and both genders from 13 unrelated families and 100 unrelated, unaffected control individuals. All patients and family members, their familiar relationship, ethnic origin, and mutations are summarized in Table I .
EDTA containing blood samples were collected from all individuals with informed consent. DNA isolation, PCR ampli®-cation, mutation detection/con®rmation, and veri®cation of paternity was carried out as previously described in detail (Frank et al, 1999a, b) .
We identi®ed 11 different mutations in the PPO gene, including three nonsense mutations (Q189X, E191X, and Q435X), four frameshift mutations (1083delT, 1091insA, 915delTG, and 1144delGT), three splice site mutations (337 + 1G®A, 1290 + 1G®C, and 1292±2 A®G), and one missense mutation (G11S) ( Table I ). Figure 1 depicts the results of our mutation detection strategy in Family 3. In heterozygous patients, the wildtype allele was distinguished from the mutant allele using a combination of conformation sensitive gel electrophoresis (CSGE) and automated sequencing on an ABI Prism 310 Genetic Analyzer from Applied Biosystems (Perkin Elmer, Foster City, CA). All mutations reported in this study were initially identi®ed by CSGE analysis as mutation screening technique. Subsequent automated sequencing of the PCR fragments showing altered mobility revealed the underlying mutations. These mutations were absent in 200 normal chromosomes studied for control purposes.
The molecular heterogeneity of VP is demonstrated by several different mutations reported in the PPO gene to date, overviews were previously given by and Whatley et al (1999) .
Interestingly, in the majority of the reported cases of VP, mutations are unique in each individual family; however, recent haplotyping analyses revealed three exceptions to this rule. Due to a founder effect, R59W is present in approximately 96% of all South African patients with VP (Meissner et al, 1996; Groenewald et al, 1998) . Recently, we showed that 1239delTACAC represents a novel founder mutation in the Chilean population, whereas R168H is the ®rst demonstrable hotspot mutation in VP (Frank et al, 2000) .
Our results re¯ect further exceptions to this rule: Two mutations, Q189X and 1144delGT, respectively, were detected in four apparently unrelated families (Table I) . Interestingly, four additional VP families carrying Q189X have been described by other investigators. The same is true for the nonsense mutation Q435X, recently also identi®ed in ®ve VP families from the U.K. (Whatley et al, 1999) . Future haplotyping analyses might elucidate the question if these nonsense mutations are due to a founder effect or represent hotspot mutations in the PPO gene.
Systematic molecular analyses and genetic counseling in families with VP are very important, in particular because an acute porphyric attack is a life-threatening condition, with a mortality ranging from 2% to 10% (Lip et al, 1993) . As clinical symptoms are not overt in children before puberty (Kauppinen and Mustajoki, 1992) , genetic analysis provides the only accurate method to identify presymptomatic mutation carriers before they are exposed to porphyrinogenic drugs or other factors that might precipitate an acute porphyric attack (Crimlisk, 1997; Moore and Hift, 1997) . Particularly in families VP1, 3, and 9, in which several children were identi®ed as mutation carriers, genetic diagnosis in the presymptomatic state provides the possibility for early comprehensive genetic counseling and should highten the attention of all physicians treating those patients. Thus, the systematic identi®ca-tion of mutation carriers within VP families is the ®rst and most important step in the prevention of acute porphyric attacks.
The data presented here provide no evidence for the existence of genotype-phenotype correlations. We did not observe a more severe phenotypic expression of certain types of mutations, e.g. those resulting in premature termination codon and thereby abolishing PPO function. In contrast, we also found no correlation between the phenotype and the underlying genetic lesion in families where several family members carried the same mutation. In family 9 (Fig 1) , for example, the severity of clinical symptoms within mutation carriers ranged from the complete absence of any symptoms to the most severe combination of extreme photosensitivity with recurrent neurologic attacks. These notions are supported by recently published studies on 104 VP families from Western Europe (Whatley et al, 1999) .
DNA analysis is clearly the method of choice to con®rm a putative diagnosis of VP, and consequently, to prevent acute attacks in presymptomatic carriers of mutations. Further investigations are underway to understand unusual mechanisms of inheritance in this disease, and to develop gene replacement strategies for this disorder. 
